Comparison of efficacy for suppression of hepatocellular carcinoma after antiviral treatment between interferon beta and ribavirin treatment and pegylated interferon alpha and ribavirin treatment

Comparison of efficacy for suppression of hepatocellular carcinoma after antiviral treatment between interferon beta and ribavirin treatment and pegylated interferon alpha and ribavirin treatment - Efficacy of interferon beta and ribavirin treatment for suppression of hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016070

Enrollment

800

Registered

2015-01-01

Start date

2009-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Interferon beta and ribavirin treatment group Pegylated interferon alpha and ribavirin treatment group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were infected with hepatitis C virus.

Exclusion criteria

Exclusion criteria: Exclusion criteria for this study were: 1. presence of hepatocellular carcinoma, 2. shortening of treatment, 3. extension of treatment, 4. positivity of HIV or hepatitis B virus surface antigen, 5. severe depression, 6. hepatic decompensation, 7. excessive active alcohol consumption or drug abuse, 8. treatment with antiviral or immnosuppressive agents

Design outcomes

Primary

Measure	Time frame
We followed the occurence of hepatocellular carcinoma after antiviral treatments.	—

Secondary

Measure	Time frame
Virological response was evaluated.	—

Countries

Japan

Contacts

Public ContactNorihiro Furusyo

Kyushu University Hospital Department of General Internal Medicine

furusyo@gim.med.kyushu-u.ac.jp0926425909

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026